Corcept Therapeutics (CORT) Retained Earnings (2010 - 2026)

Corcept Therapeutics has disclosed Retained Earnings across 17 years of filings, most recently posting $611.6 million for Q1 2026.

• Retained Earnings for Q1 2026 came in at $611.6 million, up 88285.26% year-over-year; the trailing twelve-month figure through Mar 2026 was $611.6 million (up 88285.26% YoY), and the FY2025 annual result was $2.3 million, up 1143.32% from the prior year.
• Retained Earnings came in at $611.6 million for Q1 2026 at Corcept Therapeutics, up from $2.3 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $619.1 million in Q3 2025 to a low of -$234000.0 in Q3 2023.
• The 5-year median for Retained Earnings is $279.8 million (2022), against an average of $264.9 million.
• Peak annual rise in Retained Earnings reached 219326.07% in 2024, while the deepest fall reached 135.63% in 2024.
• Corcept Therapeutics' Retained Earnings stood at $296.4 million in 2022, then tumbled by 99.79% to $609000.0 in 2023, then tumbled by 135.63% to -$217000.0 in 2024, then soared by 1143.32% to $2.3 million in 2025, then soared by 26915.28% to $611.6 million in 2026.
• The last three Retained Earnings figures came in at $611.6 million (Q1 2026), $2.3 million (Q4 2025), and $619.1 million (Q3 2025), per Business Quant data.